The Surprising Way Big Pharma Is Researching New Drugs

Trying to find new ways of approaching a common health condition can be, well, a bear -- but the country's pharmaceutical companies won't let that stand in their way.

Jan 4, 2014 at 8:00AM

Pharmaceutical companies have used animals in their research for decades. But now, the companies are expanding their subject from just rats and mice, with Amgen (NASDAQ:AMGN) leading the way with some grizzly results.


Source: Flickr; Nomadic Lass.

Hey, hey, Boo Boo! I got an obesity researcher for you!
Amgen has enlisted the help of 12 grizzly bears to help in the research for a useful obesity drug. Since upwards of 36% of the nation's population is obese, the research on bears could be helpful insight for the pharmaceutical market, which hasn't had a ton of success with the current drugs on the market.

Since bears hibernate, they are used to packing on the pounds in preparation for a long winter's nap. But unlike humans, when they put on 100 or more pounds, their bad cholesterol may hit the ceiling and their blood pressure may spike, but they aren't at any greater risk for a heart attack, stroke, or diabetes.

Researchers, lead by Dr. Kevin Corbit, are taking a look at how the bears' bodies handle the stress of the increased weight. One key may be the bear's ability to reduce its sensitivity to the hormone insulin while hibernating, which allows the body to slow down the rate at which fat and sugar are broken down for use or energy storage.

Man's best friend(s)
Bears aren't the only animals that have helped pharmaceutical researchers develop new drugs for humans. A drug from Merck (NYSE:MRK) was developed after research on narcoleptic dogs from Stanford University pointed to a specific region in the brain that acts as a switch between sleeping and wakefulness. Though it is still in the process of FDA approval and needs to be tested on more people before the full range of side effects are discovered, Suvorexant seems like a promising alternative to the traditional sleeping medications that effect the entire nervous system.

Researchers have also enlisted the help of lemon sharks to study their cancer-defying abilities, llamas for their disease-fighting antibodies, and Antarctic penguins for the effects of fasting on the body. The use of the various species has seen more success for the researchers than genetically mutated mice or rats thanks to natural predispositions to the research thesis under study.

America's big problem
The research being performed by Amgen's team at Washington State University's grizzly center is key to a major problem that the pharmaceutical industry has yet to concur. Though Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) both have FDA-approved drugs on the market -- Belviq and Qsymia, respectively -- neither company has found the silver bullet for the nation's obesity epidemic.

Historically, drugs for weight loss have been plagued by horrific side-effects. While the new generation has cut back on the adverse effects, there has also been a reduction in the efficacy of the drugs themselves. With the cons potentially outweighing the pros, both Arena and VIVUS have found that sales are not booming as they had anticipated. Though an increase in education among doctors, patients, and pharmacists may improve the sales rate for the available drugs, the research completed on grizzly bears may eventually turn the current method of obesity treatment on its head.

Thanks, Mother Nature
The pharmaceutical industry has plenty of new opportunities at its door as more researchers turn their attention to the curious health benefits enjoyed naturally by animals all over the globe. With more research into these predispositions, humans could one day have an answer to any number of health problems. But for now, the companies at the forefront of such research can be sure that they have a certain animalistic advantage over their competitors.

Making research bear-able
Research on animals isn't the only way that pharmaceutical companies are paving the way to new treatments. By taking a close look at the companies willing to shun the status quo and discovery revolutionary, groundbreaking technologies, you can find investment opportunities that others will miss. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. To get your copy today, Click here.

Fool contributor Jessica Alling and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information